Telesis Bio Inc. is a provider of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) solutions. The Company provides automated multi-omic and synthetic biology solutions focused on providing applications to enable researchers to rapidly and reproducibly build or write high-quality synthetic DNA and messenger Ribonucleic Acid (mRNA) and short oligonucleotides that are ready to use in many downstream synthetic biology enabled markets. Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Its on-market and its planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, Benchtop reagents and Custom Gibson Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS) solutions. BioXp Select kits offer customers the ability to use non-Telesis Bio DNA while using the BioXp system to perform synthetic biology workflow applications.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

Quotes

Date	Price	Change	Volume
09/02/26	0.0550 $	0.00%	151
05/02/26	0.0550 $	0.00%	937
04/02/26	0.0550 $	0.00%	527

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Delayed OTC Markets Other stock markets 14:55:31 09/02/2026 GMT			5-day change	1st Jan Change
0.0550 ^USD	0.00%		0.00%	+10.00%

28/05/25	Telesis Bio Inc. Announces Licensing Agreement with Regeneron Pharmaceuticals, Inc. to Adopt Gibson SOLA Platform for Rapid On-Site DNA and Gene Synthesis	CI
28/05/25	Telesis Bio Announces Licensing Agreement With Regeneron	RE

Capitalization	710K 599K 546K 521K 968K 64.36M 1M 6.35M 2.52M 31M 2.66M 2.61M 108M	P/E ratio 2022	-0.73x	P/E ratio 2023	-0.24x
Enterprise value	15.93M 13.43M 12.25M 11.7M 21.72M 1.44B 22.46M 142M 56.6M 695M 59.75M 58.53M 2.43B	EV / Sales 2022	0.48x	EV / Sales 2023	0.99x
Free-Float	69.33%	Yield 2022 *	-	Yield 2023	-

28/05/25	Telesis Bio Inc. Announces Licensing Agreement with Regeneron Pharmaceuticals, Inc. to Adopt Gibson SOLA Platform for Rapid On-Site DNA and Gene Synthesis	CI
28/05/25	Telesis Bio Announces Licensing Agreement With Regeneron	RE
17/03/25	Telesis Bio, Inc. announced that it expects to receive $21 million in funding	CI
07/11/24	Telesis Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
03/11/24	Telesis Bio, Inc. announced that it has received $3 million in funding	CI
25/10/24	Telesis Bio, Inc. Announces Departure of Robert H. Cutler as Chief Legal Officer	CI
01/10/24	Telesis Bio, Inc.(NasdaqGS:TBIO) dropped from S&P TMI Index	CI
27/09/24	Top Premarket Decliners	MT
26/09/24	Telesis Bio, Inc.(OTCPK:TBIO) dropped from NASDAQ Composite Index	CI
26/09/24	Sector Update: Health Care Stocks Mixed Late Afternoon	MT
26/09/24	Top Midday Gainers	MT
26/09/24	Top Premarket Gainers	MT
25/09/24	Telesis Bio, Beckman Coulter Form Partnership on DNA Synthesis Tech -- Shares Rise After Hours	MT

11/08/23	KeyBanc Downgrades Telesis Bio to Sector Weight From Overweight, Cites 'Limited Top-Line Visibility' Amid 'Tepid Biopharma Spending Environment'	MT
09/11/22	KeyBanc Capital Markets Adjusts Price Target on Codex DNA to $5 From $8, Maintains Overweight Rating	MT
28/03/22	KeyBanc Adjusts Codex DNA's Price Target to $8 From $30, Keeps Overweight Rating	MT
13/07/21	CODEX DNA : Cowen Starts Codex DNA at Outperform	MT
13/07/21	CODEX DNA : Jefferies Starts Codex DNA at Buy With $23 Price Target	MT

Telesis Bio, Inc. Share Price

Equities

TBIO

US1920032000

Advanced Medical Equipment & Technology

Valuation: Telesis Bio, Inc.

Chart: Telesis Bio, Inc.

Latest news: Telesis Bio, Inc.

Analysts' recommendations: Telesis Bio, Inc.

Press Releases: Telesis Bio, Inc.

News in other languages: Telesis Bio, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Telesis Bio, Inc.

ETFs: Telesis Bio, Inc.

Other Advanced Medical Equipment & Technology

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

29/05/25	Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA Platform for Rapid On-Site DNA and Gene Synthesis	AQ
08/11/24	Telesis Bio: Q3 Earnings Snapshot	AQ
27/09/24	Technical Explosions: DUO, KTTA, TBIO, GOTU - Watch Peraso Inc. (NASDAQ: PRSO) Now Amid Breakout Momentum!	AQ
25/09/24	Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis	AQ
10/09/24	Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market	AQ

11/09/24	MÄRKTE USA/Fest - Dow 900 Punkte über Tagestief - Inflation stützt Zinsoptimismus
11/09/24	MÄRKTE USA/Aktien schwenken nach schwächerem Start auf Erholungskurs
11/09/24	MÄRKTE USA/Aktienkurse starten nach Inflationszahlen leichter
11/09/24	MÄRKTE USA/Wall Street nach Inflationsdaten im Minus gesehen
22/03/23	MORNING BRIEFING - USA/Asien

1 month	+10.00%
3 months	+161.90%
6 months	+150.00%
Current year	+10.00%

1 week	0.06	0.06
1 month	0.01	0.06
Current year	0.01	0.06
1 year	0	1.55
3 years	0	59.76
5 years	0	462.6
10 years	0	462.6

Manager	Title	Age	Since
Eric Esser CEO	Chief Executive Officer	56	16/04/2024
Daniel Gibson CTO	Chief Tech/Sci/R&D Officer	49	31/07/2018
Jen Carroll IRC	Investor Relations Contact	-	30/11/2022

Director	Title	Age	Since
Gregory Herrema BRD	Director/Board Member	60	17/10/2023
Sarah Hlavinka McConnell BRD	Director/Board Member	61	30/06/2024
Todd Krueger BRD	Director/Board Member	-	31/07/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
TELESIS BIO, INC.	0.00%	0.00%	-85.57%	-99.83%	99.1K
THERMO FISHER SCIENTIFIC, INC.	-3.46%	-6.65%	-5.92%	-11.97%	198B
INTUITIVE SURGICAL, INC.	-3.11%	+0.84%	-18.53%	+95.95%	176B
DANAHER CORPORATION	-2.02%	-0.48%	+6.20%	-17.38%	156B
BOSTON SCIENTIFIC CORPORATION	+1.28%	-4.35%	-29.82%	+55.65%	109B
SIEMENS HEALTHINEERS AG	+0.65%	-5.70%	-30.29%	-21.39%	53.09B
EDWARDS LIFESCIENCES CORPORATION	-2.72%	-1.51%	+1.45%	-0.89%	46.04B
RESMED, INC.	-4.01%	-7.36%	+4.69%	+15.09%	37.82B
AGILENT TECHNOLOGIES, INC.	-3.01%	-3.81%	-9.69%	-19.34%	36.46B
GE HEALTHCARE TECHNOLOGIES INC.	-1.65%	-5.62%	-9.56%	+11.89%	36.1B
Average	-1.82%	-2.39%	-17.70%	+0.78%	84.82B
Weighted average by Cap.	-2.15%	-1.65%	-10.36%	+20.06%

	2022	2023
Net sales	27.44M 23.12M 21.1M 20.14M 37.4M 2.49B 38.68M 245M 97.46M 1.2B 103M 101M 4.18B	27.51M 23.18M 21.16M 20.19M 37.5M 2.49B 38.78M 246M 97.73M 1.2B 103M 101M 4.19B
Net income	-48.47M -40.85M -37.28M -35.58M -66.08M -4.39B -68.33M -433M -172M -2.12B -182M -178M -7.39B	-47.72M -40.22M -36.7M -35.03M -65.06M -4.32B -67.28M -426M -170M -2.08B -179M -175M -7.27B
Net Debt	-22.15M -18.67M -17.04M -16.26M -30.2M -2.01B -31.23M -198M -78.69M -967M -83.07M -81.37M -3.38B	15.22M 12.83M 11.71M 11.17M 20.75M 1.38B 21.46M 136M 54.08M 664M 57.09M 55.92M 2.32B